Lipid control in patients with coronary artery disease in a healthcare area in Cáceres (Spain): LIPICERES study

Gómez-Barrado, José J.; Ortiz, Carlos Humberto; Gómez-Turégano, Marta; Gómez-Turégano, Paula; Garcipérez-de-Vargas, Francisco J.; Sánchez-Calderón, Pablo

doi:10.1016/j.artere.2016.09.001

Cited by 3 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found an overall achievement rate for the risk-based LDL-C goals of only 31.1%, despite all patients being on high-intensity statins, even with 62% of them on combination therapy of high-intensity statins plus ezetimibe. Regardless of differences in the recommended LDL-C targets, baseline CV risk of patients, or LLT used for CVD prevention, our findings are consistent with several international and Spanish studies that have consistently reported low rates of LDL-C goal attainment in high-or very high-risk patients, ranging from 4% to 57% [6,[10][11][12][13][14][17][18][19][20][21][22][23][24][25][26]. It must be highlighted that most patients included in the TERESA study were categorized as very high CVD risk as they were recruited in cardiology and internal medicine units.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

Barrios

Sala

Escobar

et al. 2023

JCM

View full text Add to dashboard Cite

Despite steady improvements in cardiovascular disease (CVD) prevention, a scarce proportion of patients achieve the recommended LDL-C goals, even under high-intensity lipid-lowering therapy (LLT). Our study aimed to evaluate the attainment rate of LDL-C targets recommended by the 2019 European guidelines, and to characterize potential factors associated with LDL-C goal achievement and change patterns in LLT. We conducted a retrospective, observational study on patients treated with high-intensity atorvastatin or rosuvastatin ± ezetimibe at cardiology and internal medicine clinics across Spain. It included 1570 evaluable patients (median age: 62 years; established CVD: 77.5% [myocardial infarction: 34.3%]; and 85.8% at very high cardiovascular risk). Rosuvastatin ± ezetimibe was the LLT in 52.2% of patients, and atorvastatin ± ezetimibe in 47.8%. LLT had been modified in 36.8% of patients (side effects: 10%), being the most common switch from atorvastatin- to rosuvastatin-based treatment (77.2%). The risk-based LDL-C goal attainment rate was 31.1%, with 78.2% high-risk and 71.7% very high-risk patients not achieving the recommended LDL-C targets. Established CVD and familial hypercholesterolemia were significantly associated with the non-achievement of LDL-C goals. Although having limitations, this study shows that the guideline-recommended LDL-C goal attainment rate is still suboptimal despite using high-intensity statin therapy in a real-world setting in Spain.

show abstract

Section: Discussionsupporting

confidence: 89%

“…In the Spanish subset of the EUROASPIRE study, 49% of subjects achieved their LDL-C goals [10,11]. Similar rates were obtained in three Spanish studies, where around 55% of patients at very high CV risk achieved LDL-C <70 mg/dL [12][13][14]. Previous Spanish registries showed even lower rates of LDL-C target achievement.…”

Section: Introductionsupporting

confidence: 73%

Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

Barrios

Sala

Escobar

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…O prognóstico da doença arterial coronariana depende da adesão à terapêutica estabelecida e estudos mostram que mais de um quarto dos pacientes com DAC não consegue alcançar as metas de perfil lipídico [20]. Estima-se uma redução de 15% de eventos cardiovasculares com o uso contínuo de hipolipemiantes e anti-hipertensivos.…”

Section: Discussionunclassified

Prevalência de adesão medicamentosa em pacientes com doença arterial coronariana crônica

Sobral¹,

Gomes²,

Carvalho³

et al. 2020

Enferm Bras

View full text Add to dashboard Cite

Objetivos: Avaliar a prevalência da adesão medicamentosa do paciente com doença arterial coronariana crônica e comparar os perfis clínico, socioeconômico e angiográfico de paciente aderentes e não aderentes. Métodos: Estudo observacional, transversal, prospectivo, quantitativo e descritivo, realizado de julho a outubro de 2016, em dois hospitais, sendo um público e outro privado. Forma entrevistados 130 pacientes submetidos ao procedimento de cinecoronariografia e consultados os resultados do exame. Utilizou-se o teste de Morisky-Green para mensurar a aderência a medicação. Resultados: A taxa de adesão medicamentosa foi de 26,15%, considerada baixa. Dentre as variáveis de perfis clínico, sociodemográfico e angiográfico apenas a hipertensão foi mais prevalente nos pacientes aderentes. Conclusão: Visto que a gravidade da lesão não ter tido associação direta com a adesão, sugere-se que pesquisas posteriores considerem o risco genético como fator de risco independente.Palavras-chave: adesão à medicação, doença das coronárias, cooperação do paciente.

show abstract

“…The most recent data in Spain show improvements in the management of dyslipidemia, but the achievement of the LDL-C objective remains insufficient. In the LIPICERES registry, the achievement of LDL-C objectives in patients with stable CHD was 52.3% [16].…”

Section: In Patients With the Swedish Secondary Prevention After Heartmentioning

confidence: 99%

“…In a recent Spanish multicenter registry carried out in cardiology consultations, which included patients with CHD, only 26% of patients met the LDL-C objective, and this despite the fact that 95.3% of them received LLT [15]. More recently, the LIPICERES registry showed that 52.3% of patients with CHD achieved the LDL-C objective [16]. In the EUROASPIRE V registry, carried out in 29 European countries, only 29% of patients with previous infarction achieved the objective; however, Spain is one of the countries in which this degree of achievement of objectives higher, 48.7% [17].…”

Section: Introductionmentioning

confidence: 99%

Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry

et al. 2020

View full text Add to dashboard Cite

Background: Low-density lipoprotein cholesterol (LDL-C) contributes decisively to the development of cardiovascular disease (CVD). In the LYNX registry we determined the rate of achievement of the target value of LDL-C, the use of lipid-lowering therapy (LLT) and the predictive factors of not reaching the target in patients with stable coronary heart disease (CHD). Methods: LYNX included consecutive patients with stable CHD treated at the University Hospital of Caceres, Extremadura (Spain) from September 2016 to September 2018, and those who must have an LDL-C target below 70 mg/dL according to the European Society of Cardiology (ESC) 2016 guidelines. The variables independently associated with the breach of the LDL-C objective were evaluated by multivariable logistic regression. Results: A total of 674 patients with stable CHD were included. The average LDL-C levels were 68.3 ± 24.5 mg/dL, with 56.7% showing a level below 70 mg/dL. LLT was used by 96.7% of patients, 71.7% were treated with high-powered statins and 30.1% with ezetimibe. The risk of not reaching the target value of LDL-C was higher in women, in active smokers, and in those who had multivessel CHD or had atrial fibrillation. Patients with diabetes mellitus, those who took potent statins or co-administration treatment with ezetimibe were more likely to reach the target level of LDL-C. Conclusions: The treatment of dyslipidemia in patients with chronic CHD remains suboptimal; however, an increasing number of very high-risk patients achieve the LDL-C objective, although there is still enormous potential to improve cardiovascular outcome through the use of more intensive LLT.

show abstract

Lipid control in patients with coronary artery disease in a healthcare area in Cáceres (Spain): LIPICERES study

Cited by 3 publications

References 32 publications

Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

Prevalência de adesão medicamentosa em pacientes com doença arterial coronariana crônica

Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry

Contact Info

Product

Resources

About